http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-085304-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate | 2012-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-085304-A1 |
| titleOfInvention | IMIDAZO [5,1-F] [1,2,4] TRIAZINS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| abstract | This refers to compounds of formula (1) and pharmaceutically acceptable salts thereof, to processes for the preparation of, to intermediates used in the preparation of, and compositions containing said compounds and to the uses of said compounds as a process for the treatment of a disease or condition selected from the group consisting of disorders of the central nervous system, cognitive disorders, schizophrenia, dementia and other disorders, in a mammal. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt of the same, in which: "-A-R5" is a compound of formula (2), (3) or (4); R 1 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-15 cycloalkyl, -C 1-6 alkyl-OH, -C 1-6 alkyl-CN, -SF5, -CF3, -CHF2 or - CH2F; R2 is -C1-6-R9 alkyl, -NHR3, -N (R3) 2, -O-C1-6-R9 alkyl, -OR8, C3-15 cycloalkyl, C6-10 aryl, C1-14 heterocyclic or C1 heteroaryl -14; wherein said C3-15 cycloalkyl and C1-14 heterocyclic may optionally contain a double or triple bond and one to two oxo groups (O =); and wherein said moieties -C1-6-R9 alkyl, -NHR3, -N (R3) 2, -O-C1-6-R9 alkyl, -OR8, C3-15 cycloalkyl, C6-10 aryl, C1- heterocyclic 14 or C1-14 heteroaryl may be optionally substituted with one to three substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo and -CF3; each R3 is independently selected from the group consisting of -C1-6-R9 alkyl, -C2-6-R9 alkenyl, -C2-6-R9 alkyl-and C3-15-R9 -cycloalkyl, or when R2 is -N ( R3) 2 both of said R3 can be taken together with the nitrogen atom to which they are attached to form a 4- to 6-membered heterocyclic ring that optionally contains one or two oxo groups (O =) and are optionally substituted with one to three substituents independently selected from the group consisting of hydrogen, fluorine, -CN, -CF3, -CHF2, -CH2F, -OH, -O-C1-6 alkyl, NH2, -NH-C1-6 alkyl, -N [alkyl C1-6] 2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, - (C = O) -R8, - (C = O) -OR8, - (C = O) -N (R8) 2, -O- (C = O) -R8, -OR8, -O- (C = O) -OR8, -SR8, -S (O) R8, -S (O) 2R8, -S (O) 2N (R8) 2, -NH- (C = O) -R8, -NH- (C = O) -OR8, -O- (C = O) -N (R8) 2, -NH- (C = O) -N (R8) 2, -N [C1-6 alkyl] (C = O) -R8, -N [C1-6 alkyl] (C = O) -OR8, -N [C1-6 alkyl] (C = O) -N (R8) 2, C3-15 cycloalkyl, C6-10 aryl, C1-14 heterocyclic and C1-14 heteroaryl; wherein said C3-15 cycloalkyl and C1-14 heterocyclic may optionally contain a double or triple bond and one to two oxo groups (O =); each R4 is independently selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C2-8 alkynyl, -CF3, -CHF2, -CH2F, or C3-15 cycloalkyl; R4a is hydrogen, C1-6 alkyl, C3-4 alkenyl, C3-4 alkynyl, -CF3, -CHF2, -CH2F or C3-15 cycloalkyl; R5 is a residue selected from the group of formulas (5), in which n is 0.1, 2, 3 or 4; each R6 is independently selected from the group consisting of hydrogen, halo, C1-6 alkyl, -CF3, -CHF2, -CH2F, -CF2-C1-6 alkyl, -SF5, -CN, -C1-6-CN alkyl , -NO2, - (C = O) -R8, - (C = O) -OR8, -OR8, -O- (C = O) -N (R8) 2, -SR8, -S (O) R8, -S (O) 2R8, NH2, -NH-C1-6 alkyl, -N [C1-6 alkyl] 2, -NH- (C = O) -R8, -NH- (C = O) -OR8, - N [C1-6 alkyl] (C = O) -R8, -N [C1-6 alkyl] (C = O) -OR8, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl , C1-14 heterocyclic, C6-10 aryl and C1-14 heteroaryl; wherein said, C3-15 cycloalkyl and C1-14 heterocyclic may optionally contain a double or triple bond and one to two oxo groups (O =); each R7 is independently selected from the group consisting of hydrogen, halo, C1-6 alkyl, C2-4 alkenyl, C2-6 alkynyl, -CN, -CF3, -CHF2, -CH2F, -O-C1-6 alkyl and C3-15 cycloalkyl; each R8, whenever it appears, is independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-15 cycloalkyl, -CF3 and -CHF2; and each R9 is independently selected from the group consisting of hydrogen, halo, -CF3, -CHF2, -CH2F, -CF2-C1-6 alkyl, -CN, -C1-6-CN alkyl, -NO2, - (C = O) -R8, - (C = O) -OR8, -OR8, -O- (C = O) -N (R8) 2, -SR8, -S (O) R8, -S (O) 2R8, NH2, -NH-C1-6 alkyl, -N [C1-6 alkyl] 2, -NH- (C = O) -R8, -NH- (C = O) OR8, -N [C1-6 alkyl] ( CO) -R8, -N [C1-6 alkyl] (C = O) -OR8, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl, C1-14 heterocyclic, C6-10 aryl and C1-14 heteroaryl, wherein said, C3-15 cycloalkyl and C1-14 heterocyclic may optionally contain a double or triple bond and one to two oxo groups (O =); and wherein each of said C3-15 cycloalkyl, C1-14 heterocyclic, C6-10 aryl and C1-14 heteroaryl moieties may be optionally substituted with one to three substituents independently selected from C1-6 alkyl, C1-6 alkoxy , halo and -CF3. |
| priorityDate | 2011-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.